Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations.

Liu E, Marincola P, Oberg K.

Therap Adv Gastroenterol. 2013 Sep;6(5):412-9. doi: 10.1177/1756283X13496970.

PMID:
24003341
[PubMed]
Free PMC Article
2.

Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.

Oberstein PE, Saif MW.

Clin Med Insights Oncol. 2012;6:41-51. doi: 10.4137/CMO.S7319. Epub 2012 Jan 4.

PMID:
22253554
[PubMed]
Free PMC Article
3.

Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.

Vinik AI, Raymond E.

Therap Adv Gastroenterol. 2013 Sep;6(5):396-411. doi: 10.1177/1756283X13493878.

PMID:
24003340
[PubMed]
Free PMC Article
4.

Pancreatic neuroendocrine tumors: entering a new era.

Oberstein PE, Remotti H, Saif MW, Libutti SK.

JOP. 2012 Mar 10;13(2):169-73. Review.

PMID:
22406593
[PubMed - indexed for MEDLINE]
Free Article
5.

Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.

Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S.

Target Oncol. 2012 Sep;7(3):173-81. doi: 10.1007/s11523-012-0229-6. Epub 2012 Aug 25. Review.

PMID:
22923165
[PubMed - indexed for MEDLINE]
6.

Everolimus for advanced pancreatic neuroendocrine tumors.

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.

N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.

PMID:
21306238
[PubMed - indexed for MEDLINE]
Free Article
7.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group.

Lancet. 2011 Dec 10;378(9808):2005-12. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.

PMID:
22119496
[PubMed - indexed for MEDLINE]
8.

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Review.

PMID:
22947595
[PubMed - indexed for MEDLINE]
9.

Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.

Ito T, Okusaka T, Ikeda M, Igarashi H, Morizane C, Nakachi K, Tajima T, Kasuga A, Fujita Y, Furuse J.

Jpn J Clin Oncol. 2012 Oct;42(10):903-11. Epub 2012 Jul 31.

PMID:
22859827
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus.

Cen P, Amato RJ.

Onco Targets Ther. 2012;5:217-24. doi: 10.2147/OTT.S16289. Epub 2012 Apr 3.

PMID:
22870038
[PubMed]
Free PMC Article
11.

Everolimus in advanced solid tumors: when to start, early or late?

Pusceddu S, Tessari A, Testa I, Procopio G.

Tumori. 2014 Jan-Feb;100(1):e2-3. doi: 10.1700/1430.15827.

PMID:
24675508
[PubMed - indexed for MEDLINE]
12.

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.

Yim KL.

Cancer Manag Res. 2012;4:207-14. doi: 10.2147/CMAR.S25979. Epub 2012 Jul 31.

PMID:
22904642
[PubMed]
Free PMC Article
13.

Systemic treatment of neuroendocrine tumors with hepatic metastases.

Demirkan BH, Eriksson B.

Turk J Gastroenterol. 2012;23(5):427-37. Review.

PMID:
23161287
[PubMed - indexed for MEDLINE]
14.

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.

Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM.

Chest. 2013 Apr;143(4):955-62.

PMID:
23187897
[PubMed - indexed for MEDLINE]
15.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
[PubMed - indexed for MEDLINE]
16.

Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.

Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T; RADIANT-2 Study Group.

Oncologist. 2013;18(1):46-53. doi: 10.1634/theoncologist.2012-0263. Epub 2012 Dec 21.

PMID:
23263288
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.

Peng L, Schwarz RE.

Curr Mol Med. 2013 Mar;13(3):333-9. Review.

PMID:
23331005
[PubMed - indexed for MEDLINE]
18.

Medical treatment of neuroendocrine tumours.

Weber HC.

Curr Opin Endocrinol Diabetes Obes. 2013 Feb;20(1):27-31. doi: 10.1097/MED.0b013e32835c034f. Review.

PMID:
23221494
[PubMed - indexed for MEDLINE]
19.

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.

Wolin EM.

Cancer Lett. 2013 Jul 10;335(1):1-8. doi: 10.1016/j.canlet.2013.02.016. Epub 2013 Feb 16. Review.

PMID:
23419523
[PubMed - indexed for MEDLINE]
20.

Role of everolimus in pancreatic neuroendocrine tumors.

Goldstein R, Meyer T.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Epub 2011 Sep 20. Review.

PMID:
21932937
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk